Business Context and Reporting Period
This Form 8-K was filed by Xcyte Therapies, Inc. on March 7, 2005. The filing reports the entry into a Material Definitive Agreement with Cambrex Bio Science Walkersville, Inc. regarding the supply of tissue culture media essential for the Company's manufacturing process.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance data.
Material Changes
The primary material change is the execution of a ten-year Supply Agreement with Cambrex. Key terms include:
- Duration: Initial term of ten years, renewable for one-year terms thereafter.
- Termination Notice: Requires twelve months' prior written notice if Cambrex terminates; six months' notice if the Company terminates.
- Supplier Status: Cambrex is currently the sole provider of the required tissue culture media.
Outlook, Risks, and Management Commentary
Management highlights a significant operational risk: if Cambrex becomes unwilling or unable to supply the media, the Company would need to switch to an alternative tissue culture media. Such a transition could delay clinical trials and harm the Company's business. The full Agreement will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2005, with certain portions omitted for confidential treatment.
Investor Verification Checklist
- Verify the specific pricing and volume commitments within the full Supply Agreement once filed as an exhibit to the Form 10-Q.
- Assess the feasibility and timeline for qualifying alternative tissue culture media suppliers in case of Cambrex supply failure.
- Confirm the impact of potential clinical trial delays on the Company's cash burn rate and funding requirements.